Cargando…

Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types

BACKGROUND: SARS-CoV-2 infection results in a broad spectrum of COVID-19 disease, from mild or no symptoms to hospitalization and death. COVID-19 disease severity has been associated with some pre-existing conditions and the magnitude of the adaptive immune response to SARS-CoV-2, and a recent genom...

Descripción completa

Detalles Bibliográficos
Autores principales: Pahl, Matthew C., Le Coz, Carole, Su, Chun, Sharma, Prabhat, Thomas, Rajan M., Pippin, James A., Cruz Cabrera, Emylette, Johnson, Matthew E., Leonard, Michelle E., Lu, Sumei, Chesi, Alessandra, Sullivan, Kathleen E., Romberg, Neil, Grant, Struan F. A., Wells, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164584/
https://www.ncbi.nlm.nih.gov/pubmed/35659055
http://dx.doi.org/10.1186/s13059-022-02691-1
_version_ 1784720167852310528
author Pahl, Matthew C.
Le Coz, Carole
Su, Chun
Sharma, Prabhat
Thomas, Rajan M.
Pippin, James A.
Cruz Cabrera, Emylette
Johnson, Matthew E.
Leonard, Michelle E.
Lu, Sumei
Chesi, Alessandra
Sullivan, Kathleen E.
Romberg, Neil
Grant, Struan F. A.
Wells, Andrew D.
author_facet Pahl, Matthew C.
Le Coz, Carole
Su, Chun
Sharma, Prabhat
Thomas, Rajan M.
Pippin, James A.
Cruz Cabrera, Emylette
Johnson, Matthew E.
Leonard, Michelle E.
Lu, Sumei
Chesi, Alessandra
Sullivan, Kathleen E.
Romberg, Neil
Grant, Struan F. A.
Wells, Andrew D.
author_sort Pahl, Matthew C.
collection PubMed
description BACKGROUND: SARS-CoV-2 infection results in a broad spectrum of COVID-19 disease, from mild or no symptoms to hospitalization and death. COVID-19 disease severity has been associated with some pre-existing conditions and the magnitude of the adaptive immune response to SARS-CoV-2, and a recent genome-wide association study (GWAS) of the risk of critical illness revealed a significant genetic component. To gain insight into how human genetic variation attenuates or exacerbates disease following SARS-CoV-2 infection, we implicated putatively functional COVID risk variants in the cis-regulatory landscapes of human immune cell types with established roles in disease severity and used high-resolution chromatin conformation capture to map these disease-associated elements to their effector genes. RESULTS: This functional genomic approach implicates 16 genes involved in viral replication, the interferon response, and inflammation. Several of these genes (PAXBP1, IFNAR2, OAS1, OAS3, TNFAIP8L1, GART) were differentially expressed in immune cells from patients with severe versus moderate COVID-19 disease, and we demonstrate a previously unappreciated role for GART in T cell-dependent antibody-producing B cell differentiation in a human tonsillar organoid model. CONCLUSIONS: This study offers immunogenetic insight into the basis of COVID-19 disease severity and implicates new targets for therapeutics that limit SARS-CoV-2 infection and its resultant life-threatening inflammation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13059-022-02691-1.
format Online
Article
Text
id pubmed-9164584
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91645842022-06-04 Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types Pahl, Matthew C. Le Coz, Carole Su, Chun Sharma, Prabhat Thomas, Rajan M. Pippin, James A. Cruz Cabrera, Emylette Johnson, Matthew E. Leonard, Michelle E. Lu, Sumei Chesi, Alessandra Sullivan, Kathleen E. Romberg, Neil Grant, Struan F. A. Wells, Andrew D. Genome Biol Research BACKGROUND: SARS-CoV-2 infection results in a broad spectrum of COVID-19 disease, from mild or no symptoms to hospitalization and death. COVID-19 disease severity has been associated with some pre-existing conditions and the magnitude of the adaptive immune response to SARS-CoV-2, and a recent genome-wide association study (GWAS) of the risk of critical illness revealed a significant genetic component. To gain insight into how human genetic variation attenuates or exacerbates disease following SARS-CoV-2 infection, we implicated putatively functional COVID risk variants in the cis-regulatory landscapes of human immune cell types with established roles in disease severity and used high-resolution chromatin conformation capture to map these disease-associated elements to their effector genes. RESULTS: This functional genomic approach implicates 16 genes involved in viral replication, the interferon response, and inflammation. Several of these genes (PAXBP1, IFNAR2, OAS1, OAS3, TNFAIP8L1, GART) were differentially expressed in immune cells from patients with severe versus moderate COVID-19 disease, and we demonstrate a previously unappreciated role for GART in T cell-dependent antibody-producing B cell differentiation in a human tonsillar organoid model. CONCLUSIONS: This study offers immunogenetic insight into the basis of COVID-19 disease severity and implicates new targets for therapeutics that limit SARS-CoV-2 infection and its resultant life-threatening inflammation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13059-022-02691-1. BioMed Central 2022-06-03 /pmc/articles/PMC9164584/ /pubmed/35659055 http://dx.doi.org/10.1186/s13059-022-02691-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pahl, Matthew C.
Le Coz, Carole
Su, Chun
Sharma, Prabhat
Thomas, Rajan M.
Pippin, James A.
Cruz Cabrera, Emylette
Johnson, Matthew E.
Leonard, Michelle E.
Lu, Sumei
Chesi, Alessandra
Sullivan, Kathleen E.
Romberg, Neil
Grant, Struan F. A.
Wells, Andrew D.
Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types
title Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types
title_full Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types
title_fullStr Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types
title_full_unstemmed Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types
title_short Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types
title_sort implicating effector genes at covid-19 gwas loci using promoter-focused capture-c in disease-relevant immune cell types
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164584/
https://www.ncbi.nlm.nih.gov/pubmed/35659055
http://dx.doi.org/10.1186/s13059-022-02691-1
work_keys_str_mv AT pahlmatthewc implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT lecozcarole implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT suchun implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT sharmaprabhat implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT thomasrajanm implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT pippinjamesa implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT cruzcabreraemylette implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT johnsonmatthewe implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT leonardmichellee implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT lusumei implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT chesialessandra implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT sullivankathleene implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT rombergneil implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT grantstruanfa implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes
AT wellsandrewd implicatingeffectorgenesatcovid19gwaslociusingpromoterfocusedcapturecindiseaserelevantimmunecelltypes